Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Jason Kato"'
Autor:
Emily Tuscano, Gustavo A. Barisone, Mastewal Abuhay, Jason Kato, Robert T. O'Donnell, Ranjit S. Sidhu, Joseph Tuscano
Publikováno v:
Cancer immunology, immunotherapy : CII, vol 65, iss 10
Cancer Immunol Immunother
Cancer Immunol Immunother
In this study, the HB22.7 anti-CD22 mAb, was used for specific, targeted delivery of the potent anti-cancer agent, monomethyl auristatin E (MMAE) to non-Hodgkin lymphoma (NHL). MMAE was covalently coupled to HB22.7 through a valine-citrulline peptide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0851ce34208080ebdc9b78773ef13fe
https://doi.org/10.1007/s00262-016-1873-y
https://doi.org/10.1007/s00262-016-1873-y
Autor:
Brittany Weems, Carolina F. Reis, Hsing Jien Kung, Brianna Ribeiro, Xiaobing Wang, Don Hong Wang, Chao Yu Chen, Daniel H. Enter, Sara Ahadi, Seth Dixon, Liping Meng, Laura M. Ramirez, Leonardo J. Leon, Jason Kato, Yoshiko Maeda, Kit S. Lam, Chun Yi Wu
Publikováno v:
ACS combinatorial science, vol 18, iss 6
ACS Combinatorial Science
ACS Combinatorial Science
Identifying "druggable" targets and their corresponding therapeutic agents are two fundamental challenges in drug discovery research. The one-bead-one-compound (OBOC) combinatorial library method has been developed to discover peptides or small molec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f338b85dbbee4a5c01e2929ce5b1b6ef
https://doi.org/10.1021/acscombsci.5b00194
https://doi.org/10.1021/acscombsci.5b00194
Publikováno v:
Leukemia Research. 37:83-88
Targeted therapies, such as those using imatinib and rituximab, have revolutionized the treatment of Philadelphia chromosome-positive and CD20-positive acute lymphoblastic leukemia (ALL) respectively, yet these therapies are effective in only a subse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5094017acaa033593281ed54000601e6
https://doi.org/10.1016/j.leukres.2012.09.010
https://doi.org/10.1016/j.leukres.2012.09.010
Autor:
David Pearson, Chengyi Xiong, Jason Kato, Joseph Tuscano, David R. Gandara, Robert T. O'Donnell, Laura Newell, Yunpeng Ma
Publikováno v:
Cancer Research. 72:5556-5565
Most patients with lung cancer still die from their disease, necessitating additional options to improve treatment. Here, we provide evidence for targeting CD22, a cell adhesion protein known to influence B-cell survival that we found is also widely
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27ef69e370a5fe23efd92b933d8f7c5b
https://doi.org/10.1158/0008-5472.can-12-0173
https://doi.org/10.1158/0008-5472.can-12-0173
Autor:
Joseph Tuscano, Joyce S Lee, Yuanpei Li, Jason Kato, Juntao Luo, Kai Xiao, Robert T. O'Donnell, Kit S. Lam
Publikováno v:
Molecular Pharmaceutics. 9:1727-1735
Vincristine (VCR) is a potent anti-cancer drug but its clinical efficacy is dose-limited by severe neurotoxicity. Prophylactic and palliative treatment of VCR-induced toxicity have been explored without significant findings. The field of drug deliver
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5abab5831ce215dad27a76a3d58e3297
https://doi.org/10.1021/mp300128b
https://doi.org/10.1021/mp300128b
Publikováno v:
Oncoimmunology
Oncoimmunology, vol 1, iss 9
Oncoimmunology, vol 1, iss 9
Antibody drug conjugates (ADCs) can deliver potent drugs to cancer cells by employing the specificity of monoclonal antibodies (mAbs). ADCs have demonstrated significant anticancer activity and, in 2011, brentuximab vedotin has been approved by the F
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7632c077736bea63b7ea6abaeda1df6
https://pubmed.ncbi.nlm.nih.gov/23264893
https://pubmed.ncbi.nlm.nih.gov/23264893
Autor:
Yuanpei Li, Juntao Luo, Joyce S Lee, Kai Xiao, Tiffany A. Dong, Kit S. Lam, Abby M. Gonik, Wenwu Xiao, Jason Kato
Publikováno v:
Biomaterials. 32(27)
To minimize premature release of drugs from their carriers during circulation in the blood stream, we have recently developed reversible disulfide cross-linked micelles (DCMs) that can be triggered to release drug at the tumor site or in cancer cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5ecc4bb19ef77ed54ba7b10276c593d
https://pubmed.ncbi.nlm.nih.gov/21658763
https://pubmed.ncbi.nlm.nih.gov/21658763
Autor:
Chun-Yi Wu, Don-Hong Wang, Xiaobing Wang, Dixon, Seth M., Liping Meng, Ahadi, Sara, Enter, Daniel H., Chao-Yu Chen, Jason Kato, Leon, Leonardo J., Ramirez, Laura M., Yoshiko Maeda, Reis, Carolina F., Ribeiro, Brianna, Weems, Brittany, Hsing-Jien Kung, Lam, Kit S.
Publikováno v:
ACS Combinatorial Science; 6/13/2016, Vol. 18 Issue 6, p320-329, 10p
Publikováno v:
Drugs of the Future. 37:567
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9a68fe628b911b024d66fb9d23707b1e
https://doi.org/10.1358/dof.2012.037.08.1829209
https://doi.org/10.1358/dof.2012.037.08.1829209
Publikováno v:
Cancer Immunology, Immunotherapy; Jun2011, Vol. 60 Issue 6, p771-780, 10p